Navigation Links
AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
Date:1/11/2011

MOUNTAIN VIEW, Calif., Jan. 11, 2011 /PRNewswire/ -- AccessClosure, Inc., the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device (VCD).  With its simpler design and improved ease-of-use, Mynx Cadence offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.

(Logo:  http://photos.prnewswire.com/prnh/20110111/SF27857LOGO)

"We are extremely excited about the launch of the Mynx Cadence," said Gregory D. Casciaro, President and CEO of AccessClosure.   "Designing enhanced solutions for vascular closure is our top priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel our users have grown accustomed to.  We believe this device provides an excellent platform for growth as we continue to expand our user base."

Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy.  A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling.  Additionally, a single marker on the advancer tube removes any guesswork around sealant compression.  Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation.  These changes result in more consistent sealant delivery every time.  

"My initial experience with the Mynx Cadence has been very positive," said Elias Kassab, MD, FACC, an Interventional Cardiologist from Oakwood Hospital in Detroit, Michigan.  "The design changes inspire increased confidence in the device, but I don't feel that I've lost any of the tactile feedback I'm used to with the Mynx.  These changes truly improve the experience of deploying the Mynx."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery. The Mynx received its first FDA approval in May 2007, has been used in over 700,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.  

AccessClosure will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, in San Francisco. Gregory D. Casciaro, President and CEO, will address the conference at 4:00 p.m. PST.

About Vascular Closure

There are two methods of closing the femoral artery after cardiovascular procedures – manual compression and vascular closure devices.  Manual compression entails up to 30 minutes of firm manual pressure applied directly to the access site, which is often painful for the patient, followed by many hours of bed rest in a hospital recovery room.  Physicians frequently choose to use a vascular closure device (VCD) as an alternative to manual compression because it stops the bleeding more quickly, thereby allowing patients to leave the hospital earlier.

However, despite the benefits of VCDs, many patients find that deployment of a VCD is extremely painful.  The Mynx addresses this shortcoming by eliminating the tugging and cinching of the artery that occurs with other closure devices.  The sealant is designed for gentle placement on top of the artery without the use of a suture or permanent metal implant.  

About AccessClosure

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience.  For more information, visit our website at www.accessclosure.com.


'/>"/>
SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AccessClosure Announces Distribution Agreement for Radial Compression Band
2. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
3. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
4. Nalco Announces Price Increase
5. Vasomedical Announces Launch of Its Online Company Store
6. Mindray Medical Announces Preliminary 2010 Operating Results
7. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
8. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
9. Optimer Pharmaceuticals Announces Key Additions to Management Team
10. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
11. TriReme Medical Announces Japanese Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... breakthrough topical cream that’s the first in a new class of photodynamic cosmetics ... overall appearance of skin, visibly reduce outward signs of aging, and minimize the ...
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
Breaking Medicine News(10 mins):